Assessing research competency development in Canadian psychiatry residency programs: A systematic review and future directions.

Objective: We aimed to conduct a systematic review to identify curricular and educational interventions to build research competency among Canadian psychiatry residents and fellows transitioning to the competency-by-design framework. Methods: The PRISMA guidelines were followed, searching five databases from their inception to February 2023 for relevant evaluation-type studies exploring research competency among psychiatry residents and fellows. We appraised thestudy's quality using the Joanna Briggs Institute's risk of bias tool for observational designs. Results: Overall, 36 original articles met our inclusion criteria. Surveys (n = 10) showed that participation in scholarly research, quality improvement, or educational projects relevant to psychiatry is needed in most residency programs. However, these vary significantly across programs; few need direct research experience for residency completion. The interventions spanned four categories: externally funded comprehensive research training programs (n = 5); resident research tracks (n = 11); workshops and seminars (n = 7); and specific modules (n = 3). Reported outcomes included overall program ratings, research output, and career trajectory. The quality of most studies was low because of the lack of controls or validated metrics for evaluating outcomes. Conclusions: While many studies have explored best practices in research curricula, the current literature does not inform competency-based models for Canadian psychiatry residency programs incorporating research training requirements. Further description is needed from Canadian psychiatric training bodies regarding appropriate curricula, milestones, and metrics for evaluating research competencies.

Navigating Evidence, Challenges, and Caution in the Treatment of Stimulant Use Disorders.

Amidst the opioid epidemic, harm reduction-oriented approaches have gained traction, including interventions that focus on prescribing pharmaceutical-grade psychoactive substances, such as opioids, instead of illicit versions, intending to mitigate fatal overdose risks arising from the variability in potency and additives found in illicit drugs. Stimulants have increasingly been found in the victims of opioid overdoses, further prompting some to argue for the prescription of stimulant medications for individuals with stimulant use disorders. Yet, the evidence supporting this practice remains insufficient. In this communication, we critically examine the existing evidence, challenges, and cautions surrounding the treatment of stimulant use disorder.

Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospective cohort study.

BACKGROUND: Preliminary evidence suggest clozapine is associated with more favorable impact on concurrent substance use disorder related outcomes in patients with concurrent schizophrenia spectrum disorders (SSD). At the same time, there is a dearth of evidence with regards to clozapine outcomes in the context of concurrent methamphetamine or amphetamine use disorder (MAUD). AIMS: To examine whether clozapine use decreases rate of methamphetamine or amphetamine (MA) relapses and increases the likelihood of maintaining abstinence from any MA use. METHODS: A descriptive-analytic retrospective cohort study was conducted on individuals with SSD-MAUD in an inpatient provincial treatment and rehabilitation center for concurrent disorders. Antipsychotic exposure was categorized as "on clozapine" or "on other antipsychotic(s)." Data were collected using electronic health records. Logistic regression was used to examine association of clozapine treatment with likelihood of complete abstinence from MA use for the duration of antipsychotic exposure. Negative binomial regression was used to examine association of clozapine treatment with rate of MA relapses for the duration of antipsychotic exposure. RESULTS: The majority of the 87 included patients were male. Ethnicity was diverse, with the largest groups self-identifying as Indigenous and European. Clozapine use was both associated with increased likelihood of maintaining abstinence from MA use (adjusted odds ratio (aOR) = 3.05, 95% confidence intervals (CI) = 1.15-8.1, p = 0.025), and decreased rate of MA relapses (aRR = 0.45, 95% CI = 0.25-0.82, p = 0.009) for the duration of antipsychotic exposure. Co-prescription of psychostimulants was associated with increased rate of MA relapses (aRR = 2.43, 95% CI = 1.16-5.10, p = 0.019). CONCLUSION(S): In this study, clozapine use compared with other antipsychotics in SSD was associated with improved outcomes related to severe concurrent MAUD. Co-prescription of psychostimulant medications was associated with a poor outcome.

Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis.

BACKGROUND: Antipsychotic medications are the mainstay of treatment for schizophrenia and are associated with a reduction in psychiatric hospitalization and overall mortality. Some evidence suggest that antipsychotic medications might have a varying effect on the improvement of comorbid substance use disorders (SUDs), with clozapine showing more favorable outcomes. AIM: We systematically reviewed all available evidence on effects of clozapine on the improvement of SUDs other than nicotine. METHODS: Electronic searches of MEDLINE, Embase, PsycINFO, and CINHAL were conducted up to March 1, 2022. Studies of any methodological design involving two concepts: (1) clozapine and (2) SUD terms (excluding nicotine) were included. For SUD outcomes with three or more comparative studies with available raw data meta-analysis was performed. SUD outcomes not meeting criteria for meta-analysis were described qualitatively. Risk of bias was examined using "Downs and Black," and "Q-Coh" instruments. RESULTS: The majority of individuals in the included 31 studies were male and of European ancestry. Abstinence was the most common outcome. Most of the studies were of low-to-moderate quality, and none of the studies met all the quality criteria. Pooled findings from four observational studies in samples of patients with predominantly comorbid alcohol use disorder showed that clozapine treatment is associated with significantly higher odds of remaining abstinent. In addition clozapine was associated with decreased odds of psychiatric hospitalization in all but one observational study. CONCLUSIONS: Our systematic review and meta-analysis builds upon previous reviews, and it suggests the association of clozapine treatment with significantly higher odds of remaining abstinent from substance use and decreased likelihood of psychiatric hospitalization, compared with continuing treatment with other antipsychotic medications. Still, the validity of this association needs greater exploration and providing recommendations for the utility of clozapine in individuals without treatment-resistant psychosis and comorbid SUDs would be premature.

Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.

BACKGROUND: We aimed to determine medications' comparative efficacy and safety for adults with alcohol use disorders. METHODS: We searched eleven electronic data sources for randomized clinical trials with at least 4 weeks of treatment reporting on alcohol consumption (total abstinence and reduced heavy drinking), dropouts, and dropouts due to adverse events. We conducted network meta-analyses using random-effects, frequentist models, and calculated summary rate ratios (RRs) with 95% confidence intervals (CIs). RESULTS: We included 156 trials (N = 27,334). Nefazodone (RR = 2.11; 95% CI, 1.42-3.13), aripiprazole (RR = 1.97; 95% CI, 1.36-2.88), carbamazepine (RR = 1.85; 95% CI, 1.03-3.32), and nalmefene (RR = 1.17; 95% CI, 1.01-1.35) were associated with the most dropouts. Baclofen (RR = 0.83; 95% CI, 0.70-0.97) and pregabalin (RR = 0.63; 95% CI, 0.43-0.94) caused fewer dropouts than placebo. Nalmefene (RR = 3.26; 95% CI, 2.34-4.55), fluvoxamine (RR = 3.08; 95% CI, 1.59-5.94), and topiramate (RR=2.18; 95% CI, 1.36-3.51) caused more dropouts from adverse events over placebo. Gamma-hydroxy-butyrate (RR = 1.90; 95% CI, 1.03-3.53), baclofen (RR = 1.80; 95% CI, 1.39-2.34), disulfiram (RR = 1.71; 95% CI, 1.39-2.10), gabapentin (RR = 1.66; 95% CI, 1.04-2.67), acamprosate (RR = 1.33; 95% CI, 1.15-1.54), and oral naltrexone (RR = 1.15; 95% CI, 1.01-1.32) improved total abstinence over placebo (Fig. 3C). For reduced heavy drinking, disulfiram (RR = 0.19; 95% CI, 0.10-0.35), baclofen (RR = 0.72; 95% CI, 0.57-0.91), acamprosate (RR = 0.78; 95% CI, 0.70-0.86), and oral naltrexone (RR = 0.81; 95% CI, 0.73-0.90) were efficacious against placebo. CONCLUSIONS: The current meta-analyses provide evidence that several medications for AUDs are effective and safe and encourage the expanded use of these medications in the clinical setting. Our review found that acamprosate (2-3 g/d), disulfiram (250-500 mg/d), baclofen (30 mg/d), and oral naltrexone (50 mg/d) had the best evidence for improving abstinence and heavy drinking for patients with AUD. PROSPERO: CRD42020208946.

Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis.

BACKGROUND AND AIMS: There have been few head-to-head clinical trials of pharmacotherapies for alcohol withdrawal (AW). We, therefore, aimed to evaluate the comparative performance of pharmacotherapies for AW. METHODS: Six databases were searched for randomized clinical trials through November 2021. Trials were included after a blinded review by two independent reviewers. Outcomes included incident seizures, delirium tremens, AW severity scores, adverse events, dropouts, dropouts from adverse events, length of hospital stay, use of additional medications, total benzodiazepine requirements, and death. Effect sizes were pooled using frequentist random-effects network meta-analysis models to generate summary ORs and Cohen's d standardized mean differences (SMDs). RESULTS: Across the 149 trials, there were 10 692 participants (76% male, median 43.5 years old). AW severity spanned mild (n = 32), moderate (n = 51), and severe (n = 66). Fixed-schedule chlormethiazole (OR, 0.16; 95% CI, 0.04-0.65), fixed-schedule diazepam (OR, 0.16; 95% CI, 0.04-0.59), fixed-schedule lorazepam (OR = 0.19; 95% CI, 0.08-0.45), fixed-schedule chlordiazepoxide (OR = 0.21; 95% CI, 0.08-0.53), and divalproex (OR = 0.22; 95% CI, 0.05-0.86) were superior to placebo at reducing incident AW seizures. However, only fixed-schedule diazepam (OR, 0.19; 95% CI, 0.05-0.76) reduced incident delirium tremens. Oxcarbazepine (d = -3.69; 95% CI, -6.21 to -1.17), carbamazepine (d = -2.76; 95% CI, -4.13 to -1.40), fixed-schedule oxazepam (d = -2.55; 95% CI, -4.26 to -0.83), and γ-hydroxybutyrate (d = -1.80; 95% CI, -3.35 to -0.26) improved endpoint Clinical Institute Withdrawal Assessment for Alcohol-Revised scores over placebo. Promazine and carbamazepine were the only agents significantly associated with greater dropouts because of adverse events. The quality of evidence was downgraded because of the substantial risk of bias, heterogeneity, inconsistency, and imprecision. CONCLUSIONS: Although some pharmacotherapeutic modalities, particularly benzodiazepines, appear to be safe and efficacious for reducing some measures of alcohol withdrawal, methodological issues and a high risk of bias prevent a consistent estimate of their comparative performance.

Office-based Methadone Prescribing for Opioid Use Disorder: The Canadian Model.

In the context of the US overdose crisis, improving access to medications for opioid use disorder is urgently needed. The Canadian model of methadone treatment, whereby clinicians can prescribe methadone for opioid use disorder in office-based settings and methadone can be dispensed through community pharmacies, offers a compelling model for adoption in the US. Office-based settings in which methadone is prescribed often adopt a rapid-access model, allowing walk-in appointments and same-day initiation of methadone. Prescribing authorization requirements have been relaxed over the past 25 years to improve access to methadone. This paper summarizes the model of office-based methadone prescribing in Canada, highlighting the regulatory structures, prescribing practices, and interprofessional collaborations that enable methadone treatment in office-based settings. Potential implementation strategies for adopting office-based prescribing in the US are discussed.

Combined Yoga and Transcranial Direct Current Stimulation Increase Functional Connectivity and Synchronization in the Frontal Areas.

Transcranial direct current stimulation (tDCS) is a non-invasive neuro-stimulation technique that can modulate cortical excitability. Similarly, yoga is shown to affect the brain's neural activity and networks. Here, we aimed to investigate the effect of combined yoga and tDCS on brain oscillations and networks using resting-state electroencephalography recordings. In a randomized, cross-over, double-blind design, twenty-two healthy subjects participated in a yoga/active tDCS session (2 mA; 20 min; anode-F3, cathode F4) or yoga/sham tDCS on 2 separate days. Resting-state EEG data were collected before and after each intervention. Power spectral density (PSD) and functional connectivity, measured by a synchronization measure, phase-locking value, were computed for each condition. There were no significant differences in PSD values among the two interventions. The network-based statistic method was employed for detecting functional connectivity differences between yoga/active and yoga/sham tDCS interventions. Results show that the addition of active tDCS to yoga is associated with increased functional connectivity of the scalp and source EEG data in the frontal area. The changes were widespread, intra-hemispheric, and inter-hemispheric connections, which were mainly between the frontal area to other regions. At the source level, most of the connectivity changes were found in the fronto-parietal network. These findings suggest that combining yoga with tDCS might lead to brain network changes related to the executive and attentional functions.

Association between substance use and professional outcomes among medical students: Findings from a Canadian cross-sectional survey.

Background: While substance use is common among medical students, there is limited research on this topic involving Canadian medical students or exploring its associations with professional outcomes. The present study examines the association between Canadian medical students' substance use and related counselling attitudes and practices, career satisfaction, academic/clinical workload, and the medical school environment. Methods: We sent an electronic cross-sectional survey to students attending all 17 Canadian medical schools between November 2015 and March 2016. A total of 4,438 participants completed the survey across four years of study, with a participation rate of 40.2%. We considered four categories of substance use: cannabis, alcohol, non-medical use of prescription stimulants (NPS), and cigarettes. Covariates included professional attitudes (e.g., career satisfaction, distress, patient counselling on alcohol or smoking cessation), specialty of interest, learner mistreatment, and perceived medical school support. We used multivariate logistic regression models, generating adjusted odds ratios (AORs), to examine covariates associated with substance use and how substance use (as a covariate) was associated with different professional outcomes. Results: Individuals more interested in "lifestyle" specialties (AOR, 1.81; 95% CI, 1.08-3.05) and surgical specialties (AOR, 1.69; 95% CI, 1.16-2.47) were more likely to report excessive alcohol use. Those interested in primary care were more likely to report cannabis use in the past 12 months (AOR, 1.85; 95% CI, 1.14-3.00). We did not identify significant associations between specialty of interest and current cigarette or NPS use in the past 12 months. However, excessive alcohol use was associated with greater career satisfaction (AOR, 1.24; 95% CI: 1.04-1.49), whereas NPS in the past 12 months was associated with poorer career satisfaction (AOR, 0.63; 95% CI: 0.42-0.93). In addition, there was a negative association between NPS use and the ability to handle workloads due to physical (AOR, 0.31; 95% CI, 0.18-0.54) or mental health issues (AOR, 0.46; 95% CI, 0.30-0.71), but not for other substances. We also found significant negative associations between current cigarette use and the perceived relevance of smoking cessation counselling (AOR, 0.48; 95% CI: 0.29-0.80) and alcohol cessation counselling (AOR, 0.42; 95% CI: 0.25-0.70). Conclusions: These findings suggest that specific patterns of substance use in medical students appeared to be significantly associated with some professional outcomes, specialty of interest, and attitudes towards addiction-related clinical practice. Encouraging medical students to practise healthy habits, including minimizing harmful substance use behaviours, could be an important target for improving medical students' health and their patient care.

Contexte: Bien que la consommation d'alcool et de drogues soit courante chez les étudiants en médecine, peu d'études sur ce sujet ont été menées auprès d'étudiants canadiens en médecine ou ont exploré ses liens avec les résultats professionnels. La présente étude examine l'association entre la consommation de substances psychoactives des étudiants canadiens en médecine et les comportements et habitudes en matière de suivi psychologique, la satisfaction à l'égard de la carrière, la charge de travail universitaire/en clinique et l'environnement de la faculté de médecine. Méthodes: Nous avons fait parvenir une enquête transversale électronique aux étudiants fréquentant les 17 facultés de médecine canadiennes entre novembre 2015 et mars 2016. Au total, 4 438 participants ont répondu à l'enquête sur quatre années d'études, avec un taux de participation de 40,2 %. Nous avons considéré quatre catégories de consommation de substances : le cannabis, l'alcool, l'utilisation non médicale de stimulants sur ordonnance (NSO) et les cigarettes. Les covariables comprenaient les attitudes professionnelles (par exemple, la satisfaction professionnelle, la détresse, les conseils aux patients sur l'arrêt de l'alcool ou du tabac), la spécialité choisie, les maltraitances infligées aux étudiants et le soutien perçu de la faculté de médecine. Nous avons utilisé des modèles de régression logistique multivariés, générant des rapports de cotes ajustés (RCA), pour examiner les covariables associées à la consommation de substances et la façon dont la consommation de substances (en tant que covariable) était associée à différents résultats professionnels. Résultats: Les personnes plus intéressées par les spécialités "mode de vie" (RCA, 1,81 ; IC 95 %, 1,08-3,05) et les spécialités chirurgicales (RCA, 1,69 ; IC 95 %, 1,16-2,47) étaient plus susceptibles de déclarer une consommation excessive d'alcool. Les personnes intéressées par les soins primaires étaient plus susceptibles de déclarer avoir consommé du cannabis au cours des 12 derniers mois (RCA, 1,85 ; IC à 95 %, 1,14-3,00). Nous n'avons pas identifié d'associations significatives entre la spécialité choisie et la consommation de cigarettes ou de NSO au cours des 12 derniers mois. Toutefois, la consommation excessive d'alcool était associée à une plus grande satisfaction professionnelle (RCA, 1,24 ; IC à 95 % : 1,04-1,49), tandis que la consommation de NSO au cours des 12 derniers mois était associé à une plus faible satisfaction professionnelle (RCA, 0,63 ; IC à 95 % : 0,42-0,93). En outre, il existe une association négative entre la consommation de NSO et la capacité à gérer la charge de travail en raison de problèmes de santé physique (RCA, 0,31 ; IC à 95%, 0,18-0,54) ou mentale (RCA, 0,46 ; IC à 95%, 0,30-0,71), mais pas pour les autres substances. Nous avons également constaté des associations négatives significatives entre l'usage de la cigarette et la pertinence perçue des conseils en matière d'arrêt du tabac (RCA, 0,48 ; IC 95 % : 0,29-0,80) et des conseils en matière d'arrêt de l'alcool (RCA, 0,42 ; IC 95 % : 0,25-0,70). Conclusions: Ces résultats suggèrent que des modèles spécifiques de consommation de substances psychoactives chez les étudiants en médecine semblent être significativement associés à certains résultats professionnels, à la spécialité choisie et aux attitudes envers la pratique clinique liée à la dépendance. Encourager les étudiants en médecine à adopter des habitudes saines, notamment en minimisant les comportements nocifs liés à la consommation de substances, pourrait être un objectif important pour améliorer la santé des étudiants en médecine et les soins aux patients. Motsclés: Consommation de substances psychoactives ; Étudiants en médecine ; Enquête ; Canada.

Strategies to aid self-isolation and quarantine for individuals with severe and persistent mental illness during the COVID-19 pandemic: A systematic review.

BACKGROUND: Individuals with severe and persistent mental illness (SPMI) have a higher risk of contracting COVID-19 than individuals without SPMI. In combination with physical distancing, hygiene protocols, and vaccines, quarantine and self-isolation are primary means of viral containment. However, individuals with SPMI may experience more difficulties with mandated quarantine or self-isolation because of their illness(es), stigma, and marginalization. To date, there is a lack of consensus on strategies that could aid such individuals in completing isolation. AIM: This review aimed to synthesize evidence for interventions to support self-isolation and mandated quarantine for COVID-19 among individuals with SPMIs. METHODS: We followed the PRISMA guidelines, searching 19 electronic databases (9 published literature registries and 10 gray literature sources). We looked for relevant randomized controlled trials, quasi-experimental studies, and program evaluations of the effectiveness of relevant psychosocial, pharmacological, harm reduction, and addiction management strategies to support isolation settings or quarantine requirements for individuals with any SPMI (e.g., any mental disorder, substance use disorder, or their combination). FINDINGS: Of 10,298 total records that were located, 5582 were duplicate citations. Upon screening the remaining 4716 unique records by title and abstract, we excluded a further 3562 records. Only one original article met our inclusion criteria after reviewing the full texts of the remaining 1154 citations. To support individuals experiencing homelessness during the COVID-19 pandemic, San Francisco developed an isolation hotel that reduced COVID-19 hospital strain for 1009 participants (25% had a mental health disorder and 26% had a substance use disorder). While 81% completed their hotel stay, 48 patients had behavioral health needs that exceeded the hotel's capabilities. No other studies met our review's eligibility criteria. Most articles located by the search simply proposed solutions or discussed the challenges brought by COVID-19 for people with SPMIs. While some documents went a step further (e.g., shelter guidance documents to support individuals experiencing homelessness), these rarely addressed individuals with SPMIs directly. CONCLUSIONS: This systematic review evaluated evidence from published and gray literature on interventions to support self-isolation and mandated COVID-19 quarantine for individuals with SPMIs. Only one study met our inclusion criteria. This study found a beneficial effect of a dedicated isolation hotel for individuals experiencing homelessness and COVID-19-where approximately 25%-50% of the study sample had a mental or substance use disorder. While there has been an abundance of COVID-19 protocols in general, information for SPMIs is lacking. As the pandemic continues and we better prepare for future pandemics, developing protocols for supporting SPMIs in this context is imperative.